Avandia Lawsuits News

11/09/2011
GlaxoSmithKline (GSK) which has agreed to pay $3 billion to resolve claims it illegally marketed its Avandia diabetes drug, is facing a judge’s push to resolve most of the remaining patient lawsuits over the medication.

11/07/2011
British pharmaceutical company, GlaxoSmithKline (GSK), agreed to pay the US government $3 billion to settle criminal and civil investigations, reports Ennis & Ennis, P.A. If approved, the federal settlement will be the largest settlement for GSK, which is accused of illegally pushing its drugs.

11/04/2011
GlaxoSmithKline Plc agreed to pay $3 billion to resolve U.S. criminal and civil investigations into whether the U.K. company marketed drugs for unapproved uses and other matters, its biggest legal settlement.

09/23/2011
U.S. District Judge Cynthia M. Rufe, the presiding judge on the federal Avandia litigation cases, denied GlaxoSmithKline’s Statute of Limitations Motion to Dismiss.

06/13/2011
The U.S. Food and Drug Administration has said that starting on November 18, 2011, it will restrict retail pharmacy sales of three diabetes drugs manufactured by GlaxoSmithKline: the stand-alone Avandia (rosiglitazone) and the combination drugs Avandamet (rosiglitazone and metformin) and Avandaryl (rosiglitazone and glimepiride). The market restrictions are motivated by the agency's concerns that the drugs increase the risk of heart attacks.

More Avandia News:::

Avandia Side Effects Lawsuit
NO RECOVERY... NO FEES...NO COSTS

Avandia - Rosiglitazone is a widely prescribed medication to treat Type-2 Diabetes Mellitus, a condition which also known as Adult-Onset Diabetes. Manufactured by GlaxoSmithKline, Avandia (Rosiglitazone) was approved for the treatment of Type-2 Diabetes in the U.S. in 1999. Avandia is also contained in combination with other drugs in medications called Avandryl and Avandamet. To date, more than six (6) million people worldwide have taken the drug, and Avandia generates approximately $3.2 billion in annual sales for its manufacturer. However, on May 21, 2007, the United States Food & Drug Administration ("FDA") issued a Safety Alert regarding Avandia.  Later, on November 17, 2007 a "Black Box Warning" was issued by the FDA about a potential increase in heart attacks and heart-related chest pain in some individuals using Avandia.

The FDA Safety Alert warns that patients who are taking Avandia (rosiglitazone) - especially those who are known to have underlying heart disease or who are at high risk of heart attack (myocardial infarction) -  should speak to their physicians about their continued use of Avandia.

The FDA's Safety Alert follows a study released on the same day, which will appear in the June 14, 2007 issue of the New England Journal of Medicine. This type of study, known as a 'meta-analysis', evaluated forty-two (42) separate studies comparing patients using Avandia (rosiglitazone) to patients who were not using Avandia. This study concludes that patients taking Avandia (rosiglitazone) face a 43% increased risk of heart attack, and a 64% increased risk of dying from heart related ( cardiovascular) disease. Cardiovascular disease refers to the class of diseases that affect the heart and/or blood vessels, which includes but is not limited to heart attacks (myocardial infarction), strokes, aneurysms, congestive heart failure, and arrhythmia. As indicated above, there has not yet been a recall, nor has the FDA yet required that the manufacturer issue a black box warning label for Avandia, but in the event Avandia is subjected to a recall, this site will be updated.

ALERT - On Nov 14, 2007 the FDA ordered an Avandia Black Box Warning.

If you or a loved one have experienced an Avandia heart attack, or Avandia stroke, Avandia congestive heart failure, Avandia cardiovascular disease or if you have lost a loved one to an Avandia death you may be entitled to compensation. Contact the Avandia lawyers of Ennis & Ennis, P.A. today about an Avandia lawsuit. Call us toll free for a free, confidential case evaluation or fill out our online Avandia case evaluation form on this page.